New challenges in viral hepatitis

Gut

Volumn 61, Issue SUPPL. 1, 2012, Pages

  Thomas, David ^a   Zoulim, Fabien ^b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ DE LYON   (France)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CIRCULAR DNA; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; VIRUS DNA;

DELTA AGENT HEPATITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS DELTA VIRUS; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRAL CONTAMINATION; VIRUS CARRIER; VIRUS HEPATITIS; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS, VIRAL, HUMAN; HUMANS; VIRAL HEPATITIS VACCINES;

EID: 84860350134     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302122     Document Type: Review

References (46)

1. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276:906-8.
2. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-18. (Pubitemid 29281961)
3. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355:887-91. (Pubitemid 30137669)
4. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14. (Pubitemid 46780630)
5. Labrique AB, Zaman K, Hossain Z, et al. Epidemiology and risk factors of incident hepatitis E virus infections in rural Bangladesh. Am J Epidemiol 2010;172:952-61.
6. Nelson KE, Kmush B, Labrique AB. The epidemiology of hepatitis E virus infections in developed countries and among immunocompromised patients. Expert Rev Anti Infect Ther 2011;9:1133-48.
7. Seeff LB, Beebe GW, Hoofnagle JH, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987;316:965-70. (Pubitemid 17047919)
8. Tanaka Y, Kurbanov F, Mano S, et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 2006;130:703-14. (Pubitemid 43374521)
9. WHO. Health topics: hepatitis. http://www.who.int/topics/ hepatitis. (accessed 27 Feb 2012).
10. Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. Nat Med 2004;10: S70-6. (Pubitemid 40018229)
11. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-9.
12. Lettmeier B, Muhlberger N, Schwarzer R, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008;49:528-36.
13. Van DP, Banatvala J, Fay O, et al. Hepatitis A booster vaccination: is there a need? Lancet 2003;362:1065-71. (Pubitemid 37186887)
14. Van DP, Leroux-Roels G, Crasta P, et al. Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined hepatitis A and B vaccine. J Med Virol 2012;84:11-17.
15. Launay O, van der Vliet V, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011;305:1432-40.
16. Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011;364:236-47.
17. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55.
18. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-8. (Pubitemid 35408307)
19. Chang TT, Gish RG, De Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10. (Pubitemid 43357804)
20. Gish R, Jia JD, Locarnini S, et al. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. Published Online First: 8 February 2012. doi:10.1016/S1473-3099(11)70314-0
21. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009;137:1593-608.
22. Beaugerie L, Gerbes AL. Liver dysfunction in patients with IBD under immunosuppressive treatment: do we need to fear? Gut 2010;59:1310-11.
23. Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections. Gut 2012;61:333-6.
24. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39. (Pubitemid 46374607)
25. Meffre C, Le SY, Delarocque-Astagneau E, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010;82:546-55.
26. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-8. (Pubitemid 38736340)
27. Belloni L, Pollicino T, De NF, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A 2009;106:19975-9.
28. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. Published Online First: 9 December 2011. doi:10.1136/gutjnl- 2011-301073
29. Lutgehetmann M, Volz T, Kopke A, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 2010;52:16-24.
30. Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004;15:7-16. (Pubitemid 38096122)
31. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-83.
32. Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006;12:190-7. (Pubitemid 43214745)
33. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
34. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
35. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
36. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
37. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM- 1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75.
38. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24.
39. Volk ML, Tocco R, Saini S, et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009;50:1750-5.
40. Thomas DL. Curing hepatitis C with pills: a step toward global control. Lancet 2010;376:1441-2.
41. Dorner M, Horwitz JA, Robbins JB, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011;474:208-11.
42. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007;356:895-903. (Pubitemid 46339908)
43. Tei S, Kitajima N, Takahashi K, et al. Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 2003;362:371-3. (Pubitemid 36945060)
44. Thomas DL, Yarbough PO, Vlahov D, et al. Seroreactivity to hepatitis E virus in areas where the disease is not endemic. J Clin Microbiol 1997;35:1244-7. (Pubitemid 27175259)
45. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008;358:811-17. (Pubitemid 351281642)
46. Mallet V, Nicand E, Sultanik P, et al. Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med 2010;153:85-9.